You are here

  • Home
  • Archive
  • Volume 22, Issue 4
  • Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation

Article info

Article menu
Download PDFPDF
Aetiology/Harm
Cohort study
Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation

Authors

  • José Miguel Rivera-Caravaca Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK Department of Hematology and Clinical Oncology, Hospital General Universitario Morales Meseguer, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain PubMed articlesGoogle scholar articles
  • Gregory Y H Lip Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Gregory Y H Lip, University of Birmingham, Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK; g.y.h.lip{at}bham.ac.uk
View Full Text

Citation

Rivera-Caravaca JM, Lip GYH
Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation
BMJ Evidence-Based Medicine 2017;22:154-155.

Publication history

  • Accepted June 23, 2017
  • First published July 13, 2017.
Online issue publication 
December 06, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.